AstraZeneca may have used outdated info in coronavirus vaccine trial: US
Results
from a US trial of AstraZeneca's COVID-19 vaccine may have used
"outdated information," US federal health officials said in a
statement early Tuesday.
Late
Monday, the Data and Safety Monitoring Board said in a statement that it was
concerned that AstraZeneca may have provided an incomplete view of the efficacy data.
Late
Monday, the Data and Safety Monitoring Board said in a statement that it was
concerned that AstraZeneca the
included outdated information from that trial may have provided an incomplete
view of the efficacy data.
AstraZeneca
reported Monday that its COVID-19 vaccine provided strong protection among
adults of all ages in a long-anticipated U.S. study, a finding that could help
rebuild public confidence in the shot around the world and move it a step
closer to clearance in the U.S.
In the
study of 30,000 people, the vaccine was 79% effective at preventing symptomatic
cases of COVID-19 including in older adults. Read More
Comments
Post a Comment